610 related articles for article (PubMed ID: 23388064)
1. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
2. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
Irwin N; Pathak V; Flatt PR
Diabetes; 2015 Aug; 64(8):2996-3009. PubMed ID: 25883113
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes.
Irwin N; Montgomery IA; O'Harte FP; Frizelle P; Flatt PR
Int J Obes (Lond); 2013 Aug; 37(8):1058-63. PubMed ID: 23164696
[TBL] [Abstract][Full Text] [Related]
4. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
5. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice.
Irwin N; Frizelle P; O'Harte FP; Flatt PR
J Endocrinol; 2013 Jan; 216(1):53-9. PubMed ID: 23055535
[TBL] [Abstract][Full Text] [Related]
7. (pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes.
Irwin N; Frizelle P; O'Harte FP; Flatt PR
Biochim Biophys Acta; 2013 Aug; 1830(8):4009-16. PubMed ID: 23583730
[TBL] [Abstract][Full Text] [Related]
8. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
[TBL] [Abstract][Full Text] [Related]
9. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
[TBL] [Abstract][Full Text] [Related]
10. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
11. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Irwin N; Montgomery IA; Moffett RC; Flatt PR
Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
[TBL] [Abstract][Full Text] [Related]
12. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
[TBL] [Abstract][Full Text] [Related]
13. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.
Irwin N; Frizelle P; Montgomery IA; Moffett RC; O'Harte FPM; Flatt PR
Diabetologia; 2012 Oct; 55(10):2747-2758. PubMed ID: 22814764
[TBL] [Abstract][Full Text] [Related]
15. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression.
Montgomery IA; Irwin N; Flatt PR
Horm Metab Res; 2013 Jun; 45(6):471-3. PubMed ID: 23315994
[TBL] [Abstract][Full Text] [Related]
17. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice.
Irwin N; Montgomery IA; Flatt PR
Diabetologia; 2013 Jun; 56(6):1425-35. PubMed ID: 23462797
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
20. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]